Navigation Links
Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
Date:6/23/2008

tor currently has eight patent applications under review in the U.S. and abroad, as well as four provisional patent applications in the U.S. In addition, Raptor has licensed two provisional patent applications from Washington University and one patent application and one provisional patent application from UC San Diego.

For additional information, please visit http://www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: Raptor's ability to develop DR Cysteamine for the treatment of Cystinosis; Raptor's ability to formulate and manufacture DR Cysteamine in clinical quantities to support clinical trials; DR Cysteamine's ability to reduce side effects, reduce dosage and/or frequency of dosing in Cystinosis patients; and DR Cysteamine's ability to improve the quality of life of families affected by Cystinosis. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may inven
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
2. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
3. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
4. Raptor Pharmaceuticals Acquires Orphan Clinical Program
5. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
6. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
8. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
9. GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
10. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
11. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... WA (PRWEB) , ... August 03, 2015 , ... ... and TLD5000 diaphragm vacuum pumps to its comprehensive line of analytical laboratory equipment. ... steel valves, these versatile pumps provide a chemically resistant and maintenance-free solution for ...
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... Inc. (OTC Bulletin Board: GOVX ), a biotechnology ... announced the results of its Annual Shareholders Meeting, held on ... seven nominees for directors of the company to serve until ... are duly elected or appointed and qualified. They are: ...
... VPRIV(R) (velaglucerase alfa) for the Treatment of... -- CAMBRIDGE, Massachusetts, August 26, 2010 ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Aug. 26 CreAgri, Inc. ®  announced ... by the Australian Patent Office, Patent Number 2003249719, ... against skin damage caused by UV exposure. ... include formulations containing the two most important olive ...
Cached Biology Technology:GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 3GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 2Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 3Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 5Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 8Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 9Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations 2Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations 3
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... grow, a researcher at MIT's Picower Institute for Learning and ... of Science (PLoS) Biology that structural remodeling of neurons does ... means that it may one day be possible to grow ... cord injury, such as the one that paralyzed the late ...
... Max Planck researchers uncover how a nanoscale 'compass' inside ... The entire bacterium is oriented like a compass needle ... clear how the cells organise magnetosomes into a stable ... attraction. But using modern molecular-genetic and imaging processes, researchers ...
... Scientists from the National Institute of Allergy and ... of Health, have determined how a promising drug ... Published online this week in Proceedings of the ... scientists optimize the drug candidate, PA-824, which targets ...
Cached Biology News:MIT researcher finds neuron growth in adult brain 2MIT researcher finds neuron growth in adult brain 3Bacteria which sense the Earth's magnetic field 2Bacteria which sense the Earth's magnetic field 3Bacteria which sense the Earth's magnetic field 4NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3
ID clarifier: Without ethidium bromide...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
...
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
Biology Products: